Source: Annual Congress 2002 - Asthma: Inflammation, hyperreactivity, treatment side effects
Disease area: Airway diseases

Abstract

Eosinophilic bronchitis(EB) presents eosinophilic airway inflammation with normal spirometry and no evidence of bronchial hyperresponsiveness. It is unclear that eosinophilic bronchitis is a mild form of asthma or different airway disease.
In this study , 20 patients with eosinophilic bronchitis were included.They were divided by developed recurrent cough symptom( RCG, n=10), not recurrent coughing (NRG, n= 10) and compare the clinical parameters during the relatively long term period(up to 24 month). Clinical parameters included : cough symptom, pulmonary function, sputum eosinophil fraction, airway hyperresponsiveness.
Initially, no significant differences in these parameters were found between the two groups. In RC group, eosinophils percentages in sputum were markedly decreased in the cough free periods compared with those at the start of the study (11.2 ±] 11.8% vs 3.4 ±] 4.7%, p<0.01). In RC group, FEF25-75% significantly concurrently decreased at both the time of cough recurrence and the last follow-up time of the study compared with that at the start of the study (67.1 ±] 25.3% and 67.7 ±] 22.2% vs 80.0 ±] 27.5%, p = 0.026 and p= 0.032) .In RC group, one subject showed continuous decrease of FEV1 up to 55% of the predicted and developed dyspnea with wheezing at 9th month of the study. In NR group, two subjects showed decrease of FEV1 more than 20% without development of asthma symptoms.
Only a minority of EB develops asthma on prospective follow up. However, EB showed progressive decrease of FEV1 and FEF25-75% especially in recurrent cough group without development of asthma. In conclusion, EB is a different disease entity from the classical asthma.

Rating:

Share or cite this content

Citations should be made in the following way:
S. W. Park, D. J. Kim, J. H. Lee, Y. H. Kim, C. S. Park, S. J. Park (Bucheon Si, South Korea). Development of asthma in patients with eosinophilic bronchitis: prospective follow up study. Eur Respir J 2002; 20: Suppl. 38, 434

Member's Comments

No comment yet.

Related content which might interest you: Development of chronic airway obstructive in patients with eosinophilic bronchitis: a prospective follow up study Source: Eur Respir J 2003; 22: Suppl. 45, 423s Year: 2003 Omalizumab in severe allergic asthma associated with COPD: a multicentric cohort study Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Mepolizumab in COPD with eosinophilic bronchitis: A randomized clinical trial Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Aspiration and severe exacerbations in COPD: a prospective study Source: ERJ Open Res, 7 (1) 00735-2020; 10.1183/23120541.00735-2020 Year: 2021 Effectiveness of omalizumab in Canadian patients with allergic asthma: A retrospective study. Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Association of asthma diagnosis with chronic airflow obstruction: a multi-site cross-sectional study Source: Virtual Congress 2021 – Asthma burden and management I Year: 2021 Characteristics and outcomes of chronic cough in individuals with asthma: a population-based study Source: International Congress 2018 – Asthma and allergy in adults and children and their biomarkers Year: 2018 Neomacrolides in the treatment of patients with severe asthma and/or bronchiectasis: A retrospective observational study Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010 Experience with Mepolizumab in a cohort of patients with eosinophilic severe persistent asthma Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Chronic bronchitis phenotype in subjects with and without COPD: The PLATINO study Source: Annual Congress 2012 - COPD epidemiology Year: 2012 A retrospective cohort study demonstrating the impact of an OPEP device on exacerbations in COPD patients with chronic bronchitis Source: International Congress 2016 – Hospitalisation and comorbidities in chronic lung diseases Year: 2016 Persistence of clinical criteria of chronic bronchitis in patients with COPD over time: A longitudinal analysis of the TRACE cohort. Source: International Congress 2017 – Markers of COPD progression Year: 2017 The characteristics of work-related asthma in a prospective asthma cohort Source: International Congress 2016 – Occupational epidemiology Year: 2016 Impact of chronic cough in individuals with COPD: a population-based cohort study Source: International Congress 2019 – More and more COPD Year: 2019 Predictor of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Patients with allergic and eosinophilic asthma in the German severe asthma registry Source: International Congress 2015 – Asthma and lung immunology Year: 2015 Measuring exacerbations in subjects with mild to moderate COPD from a population-based cohort: The CanCOLD study Source: Annual Congress 2013 –Factors associated with outcomes in COPD Year: 2013 A pilot randomised clinical trial of mepolizumab in COPD with eosinophilic bronchitis Source: Eur Respir J , 49 (3) 1602486; DOI: 10.1183/13993003.02486-2016 Year: 2017 Asthma control and exacerbation rate with omalizumab in Italian patients with severe allergic asthma: PROXIMA study Source: International Congress 2017 – Asthma management Year: 2017 Effect of allergic sensitization on clinical course of patients with COPD in the Hokkaido COPD cohort study Source: International Congress 2014 – COPD physiopathology Year: 2014